ArticlePloS one2015
Inosine Improves Neurogenic Detrusor Overactivity following Spinal Cord Injury.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Molecular Mechanism Operating in Animal Models of Neurogenic Detrusor Overactivity: A Systematic Review Focusing on Bladder Dysfunction of Neurogenic Origin.International journal of molecular sciences · 2023Pooled it
- Early interventions to prevent lower urinary tract dysfunction after spinal cord injury: a systematic review.Spinal cord · 2022Pooled it
- Efficacy and Safety of Fixed Dose Combination of Inosine Monophosphate, Agmatine Sulphate, and L-Carnosine (CGXNW) as Add-on Therapy for the Management of Spinal Cord Injury - A Randomized Controlled Clinical Trial.Journal of orthopaedic case reports · 2026Article
- Integrated transcriptomic and proteomic analyses identify novel biomarkers of bladder outlet obstruction.bioRxiv : the preprint server for biology · 2026Article
- Multiomics analysis unveils an inosine-sensitive DNA damage response in neurogenic bladder after spinal cord injury.JCI insight · 2025Article
- Quantification of 11 metabolites in rat urine after exposure to organophosphates.Laboratory animal research · 2024Article
- 8-Aminopurines in the Cardiovascular and Renal Systems and Beyond.Hypertension (Dallas, Tex. : 1979) · 2023Review
- Assessing Neurogenic Lower Urinary Tract Dysfunction after Spinal Cord Injury: Animal Models in Preclinical Neuro-Urology Research.Biomedicines · 2023Review
- Molecular Mechanisms of Neurogenic Lower Urinary Tract Dysfunction after Spinal Cord Injury.International journal of molecular sciences · 2023Review
- Molecular approaches for spinal cord injury treatment.Neural regeneration research · 2023Review
- Purine nucleoside phosphorylase as a target to treat age-associated lower urinary tract dysfunction.Nature reviews. Urology · 2022Review
- Gabapentin add-on therapy for patients with spinal cord injury associated neurogenic overactive detrusors that are unresponsive to combined anticholinergic and beta-3 adrenergic therapy.Central European journal of urology · 2021Article
- Dysregulated Purine Metabolism Contributes to Age-Associated Lower Urinary Tract Dysfunctions.Advances in geriatric medicine and research · 2021Article
- Inosine as a Tool to Understand and Treat Central Nervous System Disorders: A Neglected Actor?Frontiers in neuroscience · 2021Review
- Purine nucleoside phosphorylase inhibition ameliorates age-associated lower urinary tract dysfunctions.JCI insight · 2020Article
- Inosine - a Multifunctional Treatment for Complications of Neurologic Injury.Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2018Review
- Nanofiber Scaffolds as Drug Delivery Systems to Bridge Spinal Cord Injury.Pharmaceuticals (Basel, Switzerland) · 2017Review
- Inosine attenuates spontaneous activity in the rat neurogenic bladder through an AScientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
Neurogenic detrusor overactivity and the associated loss of bladder control are among the most challenging complications of spinal cord injury (SCI). Anticholinergic agents are the mainstay for medical treatment of detrusor overactivity. However, their use is limited by significant side effects such that a search for new treatments is warranted. Inosine is a naturally occurring purine nucleoside with neuroprotective, neurotrophic and antioxidant effects that is known to improve motor function in preclinical models of SCI. However, its effect on lower urinary tract function has not been determined. The objectives of this study were to determine the effect of systemic administration of inosine on voiding function following SCI and to delineate potential mechanisms of action. Sprague-Dawley rats underwent complete spinal cord transection, or cord compression by application of an aneurysm clip at T8 for 30 sec. Inosine (225 mg/kg) or vehicle was administered daily via intraperitoneal injection either immediately after injury or after a delay of 8 wk. At the end of treatment, voiding behavior was assessed by cystometry. Levels of synaptophysin (SYP), neurofilament 200 (NF200) and TRPV1 in bladder tissues were measured by immunofluorescence imaging. Inosine administration decreased overactivity in both SCI models, with a significant decrease in the frequency of spontaneous non-voiding contractions during filling, compared to vehicle-treated SCI rats (p<0.05), including under conditions of delayed treatment. Immunofluorescence staining demonstrated increased levels of the pan-neuronal marker SYP and the Adelta fiber marker NF200, but decreased staining for the C-fiber marker, TRPV1 in bladder tissues from inosine-treated rats compared to those from vehicle-treated animals, including after delayed treatment. These findings demonstrate that inosine prevents the development of detrusor overactivity and attenuates existing overactivity following SCI, and may achieve its effects through modulation of sensory neurotransmission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.